ADPHEN Drug Patent Profile
✉ Email this page to a colleague
When do Adphen patents expire, and when can generic versions of Adphen launch?
Adphen is a drug marketed by Ferndale Labs and is included in one NDA.
The generic ingredient in ADPHEN is phendimetrazine tartrate. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adphen
A generic version of ADPHEN was approved as phendimetrazine tartrate by VIRTUS on December 31st, 1969.
Summary for ADPHEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ADPHEN at DailyMed |
US Patents and Regulatory Information for ADPHEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ferndale Labs | ADPHEN | phendimetrazine tartrate | TABLET;ORAL | 083655-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |